1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20663
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMinas, V.en
dc.contributor.authorRolaki, A.en
dc.contributor.authorKalantaridou, S. N.en
dc.contributor.authorSidiropoulos, J.en
dc.contributor.authorMitrou, S.en
dc.contributor.authorPetsas, G.en
dc.contributor.authorJeschke, U.en
dc.contributor.authorParaskevaidis, E. A.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorChrousos, G. P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorMakrigiannakis, A.en
dc.date.accessioned2015-11-24T19:09:10Z-
dc.date.available2015-11-24T19:09:10Z-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20663-
dc.rightsDefault Licence-
dc.subjectApoptosis/immunologyen
dc.subjectBlotting, Westernen
dc.subjectCaspases/metabolismen
dc.subjectCell Line, Tumoren
dc.subjectCell Proliferationen
dc.subjectCorticotropin-Releasing Hormone/genetics/*metabolism/physiologyen
dc.subjectFas Ligand Protein/genetics/immunology/*metabolismen
dc.subjectFemaleen
dc.subjectFluorescent Antibody Technique, Indirecten
dc.subjectGene Expression Regulation, Neoplasticen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectLymphocytes/cytology/immunology/metabolismen
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/genetics/metabolism/*pathologyen
dc.subjectRNA, Messenger/genetics/metabolismen
dc.subjectReceptors, Corticotropin-Releasing Hormone/genetics/metabolismen
dc.subjectReverse Transcriptase Polymerase Chain Reactionen
dc.subjectUp-Regulationen
dc.titleIntratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulationen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1038/sj.bjc.6603918-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17667919-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v97/n5/pdf/6603918a.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractAlthough corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established. FasL plays an important role in promoting tumour cells' ability to counterattack immune cells. Here, we examined immunohistochemically the expression of CRH, CRHR1, CRHR2 and FasL in 47 human ovarian cancer cases. The ovarian cancer cell lines OvCa3 and A2780 were further used to test the hypothesis that CRH might contribute to the immune privilege of ovarian tumours, by modulating FasL expression on the cancer cells. We found that CRH, CRHR1, CRHR2 and FasL were expressed in 68.1, 70.2, 63.8 and 63.8% of the cases respectively. Positivity for CRH or FasL expression was associated with higher tumour stage. Finally, CRH increased the expression of FasL in OvCa3 and A2780 cells through CRHR1 thereby potentiated their ability to induce apoptosis of activated peripheral blood lymphocytes. Corticotropin-releasing hormone produced by human ovarian cancer might favour survival and progression of the tumour by promoting its immune privilege. These findings support the hypothesis that CRHR1 antagonists could potentially be used against ovarian cancer.en
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Minas-2007-Intratumoral CRH mod.pdf446.71 kBAdobe PDFView/Open
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons